<DOC>
	<DOC>NCT02048059</DOC>
	<brief_summary>This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.</brief_summary>
	<brief_title>ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases</brief_title>
	<detailed_description>See above.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1. ≥ 18 years old 2. Breast cancer 3. Recurrent brain metastases from breast cancer 4. At least one radiologicallyconfirmed and measurable metastatic brain lesion ( ≥ 0.5 cm) 5. Neurologically stable 6. Karnofsky Performance Status (KPS) score ≥ 70 1. Prior treatment with ANG1005/GRN1005 2. Pregnancy or lactation 3. Inadequate bone marrow reserve 4. Any evidence of severe or uncontrolled diseases 5. Patients with the presence of an infection including abscess or fistulae, or known infection with hepatitis B or C or HIV 6. CNS disease requiring immediate neurosurgery intervention (e.g., resection, shunt placement, etc.) 7. Known allergy to paclitaxel or any of its components</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ANG1005</keyword>
	<keyword>GRN1005</keyword>
	<keyword>LRP-1</keyword>
	<keyword>Targeted therapy</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Brain metastases</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Blood-brain barrier</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Breast cancer with brain metastases</keyword>
	<keyword>Triple Negative</keyword>
	<keyword>TNBC</keyword>
	<keyword>HER2-positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Metastatic brain tumors</keyword>
</DOC>